NCT01733628View on ClinicalTrials.gov

Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal Cancer

CompletedOBSERVATIONAL
Enrollment

143

Participants

Timeline

Start Date

October 23, 2012

Primary Completion Date

December 19, 2017

Study Completion Date

December 19, 2017

Conditions
Metastatic Colorectal CancerMetastatic Breast Cancer
Trial Locations (10)

15006

Complejo Hospitalario Universitario A Coruña, A Coruña

Unknown

Hospital General Universitario de Elche, Elche

Hospital General Universitario de Alicante, Alicante

Complejo Hospitalario Universitario Reina Sofía, Córdoba

Complejo Hospitalario de Jaén, Jaén

Centro Oncológico MD Anderson, Madrid

Hospital General Universitario Gregorio Marañón, Madrid

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario La Fe, Valencia

Hospital Universitario Miguel Servet, Zaragoza

All Listed Sponsors
collaborator

Roche Farma, S.A

INDUSTRY

lead

Spanish Breast Cancer Research Group

OTHER

NCT01733628 - Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal Cancer | Biotech Hunter | Biotech Hunter